Relay Therapeutics, Inc.
RLAY
$7.77
$0.283.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.36M | 8.36M | 7.68M | 10.01M | 10.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.36M | 8.36M | 7.68M | 10.01M | 10.01M |
| Cost of Revenue | 267.60M | 276.33M | 306.85M | 315.44M | 324.88M |
| Gross Profit | -259.24M | -267.97M | -299.17M | -305.43M | -314.87M |
| SG&A Expenses | 65.55M | 72.79M | 79.18M | 80.24M | 80.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 333.14M | 349.12M | 386.03M | 395.68M | 404.96M |
| Operating Income | -324.79M | -340.76M | -378.35M | -385.67M | -394.96M |
| Income Before Tax | -297.59M | -311.55M | -333.39M | -337.71M | -345.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -297.59 | -311.55 | -333.39 | -337.71 | -345.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -297.59M | -311.55M | -333.39M | -337.71M | -345.20M |
| EBIT | -324.79M | -340.76M | -378.35M | -385.67M | -394.96M |
| EBITDA | -320.49M | -335.85M | -373.07M | -380.21M | -389.45M |
| EPS Basic | -1.75 | -1.95 | -2.23 | -2.40 | -2.61 |
| Normalized Basic EPS | -1.09 | -1.21 | -1.45 | -1.56 | -1.71 |
| EPS Diluted | -1.75 | -1.95 | -2.23 | -2.40 | -2.61 |
| Normalized Diluted EPS | -1.09 | -1.21 | -1.45 | -1.56 | -1.71 |
| Average Basic Shares Outstanding | 680.22M | 648.06M | 609.62M | 571.23M | 528.65M |
| Average Diluted Shares Outstanding | 680.22M | 648.06M | 609.62M | 571.23M | 528.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |